Ensysce Biosciences (ENSC) investor relations material

Executive summary

• Focused on developing abuse- and overdose-resistant pain medications, with lead candidate PF614 in Phase 3 and PF614-MPAR in Phase 1b clinical trials.

• Achieved 50% interim enrollment in pivotal PF614-301 Phase 3 trial for pain management.

• Published first peer-reviewed clinical data validating MPAR overdose-protection technology.

• Expanded patent estate for opioid and ADHD programs, including European patent allowance for PF8026.

• Initiated formal review of strategic alternatives, including partnerships and licensing.

Financial highlights

• Revenue from federal grants was $1.0 million for Q1 2026, down from $1.3 million in Q1 2025 due to timing of research activities.

• Research and development expenses rose to $3.3 million from $1.9 million year-over-year, driven by increased clinical activity for PF614.

• General and administrative expenses decreased to $1.2 million from $1.4 million year-over-year.

• Net loss attributable to common stockholders was $3.6 million in Q1 2026, compared to $1.9 million in Q1 2025.

• Cash and cash equivalents were $0.7 million as of March 31, 2026, down from $4.3 million at year-end 2025.

Outlook and guidance

• Current cash resources expected to fund operations through late Q2 2026; substantial doubt exists about ability to continue as a going concern without additional capital.

• Ongoing need for significant funding to support clinical trials, regulatory submissions, and potential commercialization.

• Board reviewing strategic alternatives to accelerate platform development and unlock shareholder value.

• Future expenses expected to remain elevated, especially for research and development.